 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 1 | 1/1 | 返回列表 |
| 查看: 335 | 回復: 0 | ||
三葉草王鐵蟲 (正式寫手)
|
[求助]
翻譯
|
|
The most discriminating models in our study included CTM. The rarity of such disease derived cell clusters, ranging from a few cells aggregated together to “mega-clusters,” and recent molecular characteriza tions describing their EMT phenotype suggest that clusters may be a more “cancerous” subtype of putative CTCs. Our data recapitulated this clinically as CTM were the strongest diagnostic in our models using not only a candidate-driven approach, but when employing a lasso model that agnostically selected CTM as the most important HD-CTC feature along with other clinical data. We also found that, unsurprisingly, the HD-CTC assay will detect CTC-like events in high-risk patients with other competing diagnoses This suggests that, although enumeration appears to be clinically useful, even sensitive methods for detecting CTCs will benefit from additional molecular characterization to differentiate circulating epithelial cells (CECs) from CTCs regardless of platform type. Using additional protein biomarkers, next generation sequencing for single mutational or whole genome copy number variation analysis to define cells with pathognom -onic hallmarks of cancer is one way to approach this issue that we are currently investigating. Whether inconsequential CECs arise from competing inflammatory lesions other than lung cancer or clinically undetected premalignant lesions remains a question that will be answered over time as the patient cohort matures. we acknowledge that its observational nature may have led to several biases in the collection of the data that render its findings preliminary. These include ：an inherent spectrum bias at participating centers; the inclusion of patients who only underwent PET-CT that may have led to identifying larger benign lesions than one would normally see in an evaluation setting; an additional bias toward identifying larger benign lesions that had a more expeditious work-up compared to smaller lesions that remain indeterminate (and thusly excluded from our analysis) and are being followed over time. |
回復此樓» 猜你喜歡
303求調(diào)劑
已經(jīng)有6人回復
-
306求調(diào)劑
已經(jīng)有4人回復
-
求調(diào)劑
已經(jīng)有6人回復
-
275求調(diào)劑
已經(jīng)有5人回復
-
求調(diào)劑
已經(jīng)有7人回復
-
考研調(diào)劑
已經(jīng)有4人回復
-
285求調(diào)劑
已經(jīng)有6人回復
-
一志愿北京化工大學070300 學碩336求調(diào)劑
已經(jīng)有7人回復
-
318求調(diào)劑
已經(jīng)有6人回復
-
305分求調(diào)劑（食品工程）
已經(jīng)有5人回復
相關(guān)版塊跳轉(zhuǎn)
我要訂閱樓主 三葉草王 的主題更新
| 1 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 考研調(diào)劑 +4 | 來好運來來來 2026-03-21 | 4/200 |
|
|---|---|---|---|---|
|
[考研] 285求調(diào)劑 +6 | ytter 2026-03-22 | 6/300 |
|
|
|
[考研] 生物學調(diào)劑 +4 | Surekei 2026-03-21 | 4/200 |
|
|
|
[考研] 求調(diào)劑 +3 | 13341 2026-03-20 | 3/150 |
|
|
|
[考研] 278求調(diào)劑 +9 | 煙火先于春 2026-03-17 | 9/450 |
|
|
|
[考研] 317求調(diào)劑 +9 | 申子申申 2026-03-19 | 15/750 |
|
|
|
[考研] 296求調(diào)劑 +4 | www_q 2026-03-20 | 4/200 |
|
|
|
[考研] 277材料科學與工程080500求調(diào)劑 +6 | 自由煎餅果子 2026-03-16 | 6/300 |
|
|
|
[基金申請]
學校已經(jīng)提交到NSFC，還能修改嗎？
 40+4
|
babangida 2026-03-19 | 9/450 |
|
|
|
[考研] 279分求調(diào)劑 一志愿211 +14 | chaojifeixia 2026-03-19 | 15/750 |
|
|
|
[考研] 301求調(diào)劑 +10 | yy要上岸呀 2026-03-17 | 10/500 |
|
|
|
[考研] 304求調(diào)劑 +6 | 曼殊2266 2026-03-18 | 6/300 |
|
|
|
[考研] 一志愿西南交大，求調(diào)劑 +5 | 材化逐夢人 2026-03-18 | 5/250 |
|
|
|
[考研] 330求調(diào)劑 +4 | 小材化本科 2026-03-18 | 4/200 |
|
|
|
[考研] 廣西大學家禽遺傳育種課題組2026年碩士招生（接收計算機專業(yè)調(diào)劑） +3 | 123阿標 2026-03-17 | 3/150 |
|
|
|
[考研] 0856調(diào)劑，是學校就去 +8 | sllhht 2026-03-19 | 9/450 |
|
|
|
[考研] 085600材料與化工調(diào)劑 324分 +10 | llllkkkhh 2026-03-18 | 12/600 |
|
|
|
[考研] 0703化學調(diào)劑 +5 | pupcoco 2026-03-17 | 8/400 |
|
|
|
[考研] 085600材料與化工求調(diào)劑 +6 | 緒幸與子 2026-03-17 | 6/300 |
|
|
|
[考研] 070303 總分349求調(diào)劑 +3 | LJY9966 2026-03-15 | 5/250 |
|